| 1 |
Zhulina Y, Udumyan R, Tysk C, Halfvarson J. Mortality in patients with Crohn's disease in Örebro, Sweden 1963-2010. Scand J Gastroenterol 2021;:1-7. [PMID: 34693837 DOI: 10.1080/00365521.2021.1991466] [Reference Citation Analysis]
|
| 2 |
Rundquist S, Sachs MC, Eriksson C, Olén O, Montgomery S, Halfvarson J; SWIBREG Study Group. Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.Aliment Pharmacol Ther. 2021;53:471-483. [PMID: 33340426 DOI: 10.1111/apt.16193] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
|
| 3 |
Ludvigsson JF, Holmgren J, Grip O, Halfvarson J, Askling J, Sachs MC, Olén O. Adult-onset inflammatory bowel disease and rate of serious infections compared to the general population: a nationwide register-based cohort study 2002-2017. Scand J Gastroenterol 2021;:1-11. [PMID: 34369254 DOI: 10.1080/00365521.2021.1924259] [Reference Citation Analysis]
|
| 4 |
Lo B, Vind I, Vester-andersen MK, Burisch J. Validation of ulcerative colitis and Crohn’s disease and their phenotypes in the Danish National Patient Registry using a population-based cohort. Scandinavian Journal of Gastroenterology 2020;55:1171-5. [DOI: 10.1080/00365521.2020.1807598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 5 |
Freeman K, Taylor-Phillips S, Willis BH, Ryan R, Clarke A. Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the IMRD-UK data. BMJ Open 2021;11:e044177. [PMID: 33619196 DOI: 10.1136/bmjopen-2020-044177] [Reference Citation Analysis]
|
| 6 |
Everhov ÅH, Kalman TD, Söderling J, Nordenvall C, Halfvarson J, Ekbom A, Ludvigsson JF, Olén O, Myrelid P. Probability of Stoma in Incident Patients With Crohn's Disease in Sweden 2003-2019: A Population-based Study. Inflamm Bowel Dis 2021:izab245. [PMID: 34618020 DOI: 10.1093/ibd/izab245] [Reference Citation Analysis]
|
| 7 |
Yu K, Faye AS, Wen T, Guglielminotti JR, Huang Y, Wright JD, D'Alton ME, Friedman AM. Outcomes during delivery hospitalisations with inflammatory bowel disease. BJOG 2022;129:1073-83. [PMID: 35152548 DOI: 10.1111/1471-0528.17039] [Reference Citation Analysis]
|
| 8 |
Halfvarson J, Ludvigsson JF, Bresso F, Askling J, Sachs MC, Olén O. Age determines the risk of familial inflammatory bowel disease-A nationwide study. Aliment Pharmacol Ther 2022. [PMID: 35460098 DOI: 10.1111/apt.16938] [Reference Citation Analysis]
|
| 9 |
Mouratidou N, Malmborg P, Järås J, Sigurdsson V, Sandström O, Fagerberg UL, Bröms G, Ludvigsson JF, Olén O; SWIBREG Study Group. Identification of Childhood-Onset Inflammatory Bowel Disease in Swedish Healthcare Registers: A Validation Study. Clin Epidemiol 2022;14:591-600. [PMID: 35520278 DOI: 10.2147/CLEP.S358031] [Reference Citation Analysis]
|
| 10 |
Axelrad JE, Sachs MC, Ludvigsson JF, Olén O; SWIBREG Study Group. A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data. Clin Epidemiol 2020;12:1059-72. [PMID: 33116900 DOI: 10.2147/CLEP.S265404] [Reference Citation Analysis]
|
